We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-6.58%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.73B
AUM Growth
-$470M
Cap. Flow
-$39.5M
Cap. Flow %
-1.06%
Top 10 Hldgs %
36%
Holding
129
New
6
Increased
41
Reduced
23
Closed
9

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$46.8M
2
PEN icon
Penumbra
PEN
+$38.2M
3
BPMC
Blueprint Medicines
BPMC
+$26.6M
4
ABOS icon
Acumen Pharmaceuticals
ABOS
+$17.4M
5
AMGN icon
Amgen
AMGN
+$17M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$44.5M
2
PODD icon
Insulet
PODD
+$40.1M
3
CNMD icon
CONMED
CNMD
+$27.9M
4
ABCM
Abcam PLC
ABCM
+$26M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.04%
2 Consumer Staples 1.17%
3 Industrials 0.83%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLK
51
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$24.7M 0.66%
1,676,500
+22,500
+1% +$377K
AZTA icon
52
Azenta
AZTA
$1.54B
$24M 0.64%
477,500
+7,600
+2% +$382K
BMRN icon
53
BioMarin Pharmaceuticals
BMRN
$13.3B
$23.4M 0.63%
264,500
– –
NVRO
54
DELISTED
NEVRO CORP.
NVRO
$23.3M 0.62%
1,211,600
+200
+0% +$4.27K
IMTX icon
55
Immatics
IMTX
$1.33B
$21.7M 0.58%
1,875,466
-660,678
-26% -$7.88M
KYMR icon
56
Kymera Therapeutics
KYMR
$9.03B
$20.9M 0.56%
1,504,351
+16,800
+1% +$338K
WRBY icon
57
Warby Parker
WRBY
$3.26B
$20.7M 0.56%
1,575,000
+250,000
+19% +$3.25M
RVMD icon
58
Revolution Medicines
RVMD
$44.4B
$20.1M 0.54%
725,152
+22,440
+3% +$666K
MRUS
59
DELISTED
Merus
MRUS
$19.8M 0.53%
838,428
+359,897
+75% +$8.73M
AMGN icon
60
Amgen
AMGN
$226B
$18.3M 0.49%
+68,000
New +$17M
BCRX icon
61
BioCryst Pharmaceuticals
BCRX
$2.51B
$18.1M 0.48%
2,551,226
+54,033
+2% +$388K
IRON icon
62
Disc Medicine
IRON
$3.01B
$17.1M 0.46%
363,468
– –
TVTX icon
63
Travere Therapeutics
TVTX
$5.74B
$16.2M 0.43%
1,807,742
+280,022
+18% +$3.95M
INZY
64
DELISTED
Inozyme Pharma
INZY
$15.5M 0.41%
3,681,174
+253,090
+7% +$1.29M
CLDX icon
65
Celldex Therapeutics
CLDX
$3.37B
$13.8M 0.37%
500,101
+78,486
+19% +$2.46M
FOLD
66
DELISTED
Amicus Therapeutics
FOLD
$12.9M 0.35%
1,063,806
– –
COLL icon
67
Collegium Pharmaceutical
COLL
$882M
$12.6M 0.34%
562,000
-88,000
-14% -$2.01M
IMGN
68
DELISTED
Immunogen Inc
IMGN
$12.1M 0.32%
759,365
+646,745
+574% +$10.8M
ABOS icon
69
Acumen Pharmaceuticals
ABOS
$176M
$11.7M 0.31%
+2,812,579
New +$17.4M
MLYS icon
70
Mineralys Therapeutics
MLYS
$2.41B
$11.1M 0.3%
1,167,492
– –
CMPX icon
71
Compass Therapeutics
CMPX
$400M
$10.9M 0.29%
5,513,788
– –
KRYS icon
72
Krystal Biotech
KRYS
$9.81B
$10.5M 0.28%
90,560
+55,659
+159% +$6.79M
MREO
73
Mereo BioPharma
MREO
$43.5M
$9.9M 0.27%
7,676,481
+634,090
+9% +$841K
FOCL
74
EDAP TMS S.A.
FOCL
$228M
$9.55M 0.26%
1,360,000
+173,700
+15% +$1.38M
INSP icon
75
Inspire Medical Systems
INSP
$1.73B
$8.83M 0.24%
+44,500
New +$11.2M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Rock Springs Capital Management held 129 positions worth $3.73B, down 11% from $4.2B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management's Q3 2023 filing shows 6 new, 41 increased, 23 reduced and 9 closed positions. Its largest new stake was Acumen Pharmaceuticals: 2,812,579 shares worth $11.7M. The largest sale was argenx, an estimated $44.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q3 2023 buy was Acumen Pharmaceuticals: 2,812,579 shares worth $11.7M.
  • Rock Springs Capital Management added most to Boston Scientific in Q3 2023, an estimated $46.8M increase.
  • Rock Springs Capital Management's biggest Q3 2023 reduction was argenx, cutting an estimated $44.5M.
  • Rock Springs Capital Management fully exited CONMED in Q3 2023, selling an estimated $27.9M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $3.73B portfolio in Q3 2023.
  • Rock Springs Capital Management opened 6 new positions and closed 9 in Q3 2023.
  • Rock Springs Capital Management's portfolio value fell 11% quarter-over-quarter to $3.73B.

Based on Rock Springs Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.